Zoledronic acid (ZA) has been shown to be beneficial against cancer both directly and
indirectly. However, because of its fast absorption by bone, its use in extraskeletal
malignancies has been limited. Due to its quick blood clearance, ZA is less effective as a
cancer treatment. To utilize the numerous therapeutic properties of ZA, novel delivery
strategies are necessary. While maintaining its pharmacological properties, nanomedicine is
an excellent method of increasing ZA's circulatory half-life and intratumor accumulation …